Detection of HIV-1 neutralizing antibodies in a human CD4 +/CXCR4+/CCR5+ T-lymphoblastoid cell assay system

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  McLinden, Robert J ^a   LaBranche, Celia C ^b   Chenine, Agnès Laurence ^a   Polonis, Victoria R ^a   Eller, Michael A ^a   Wieczorek, Lindsay ^a   Ochsenbauer, Christina ^c   Kappes, John C ^c,d   Perfetto, Stephen ^e   Montefiori, David C ^b   Michael, Nelson L ^a   Kim, Jerome H ^a  

^a WRAIR   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRANSACTIVATOR PROTEIN; VIRUS ANTIGEN;

ANTIBODY DETECTION; ARTICLE; CELL ASSAY; CELL STIMULATION; CONTROLLED STUDY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOBLASTOID CELL LINE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPORTER GENE; STABLE EXPRESSION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GENE EXPRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; NEUTRALIZATION TESTS; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 84896691215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077756     Document Type: Article

References (103)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
2. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
3. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M et al. (2004) Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190: 702-706. doi:10.1086/422258. PubMed: 15272397. (Pubitemid 39049999)
4. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. doi:10.1056/NEJMoa1113425. PubMed: 22475592.
5. Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444. doi:10.1146/annurev-immunol-030409-101256. PubMed: 20192810.
6. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455: 613-619. doi:10.1038/nature07352. PubMed: 18833271.
7. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by pasive infusion of neutralizing antibodies. Nat Med 6: 207-210. doi:10.1038/72318. PubMed: 10655111. (Pubitemid 30082367)
8. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347. doi:10.1128/JVI.75.17.8340-8347. 2001. PubMed: 11483779. (Pubitemid 32743706)
9. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W et al. (2000) Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6: 200-206. doi:10.1038/72309. PubMed: 10655110. (Pubitemid 30082366)
10. Wrin T, Nunberg JH (1994) HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. AIDS 8: 1622-1623. doi:10.1097/00002030-199411000-00017. PubMed: 7848602. (Pubitemid 24335103)
11. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-348. doi:10.1093/infdis/173.2.340. PubMed: 8568294. (Pubitemid 26042433)
12. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC et al. (1998) Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12: 2407-2415. doi:10.1097/00002030-199818000-00009. PubMed: 9875578. (Pubitemid 28558598)
13. Bures R, Gaitan A, Zhu T, al e (2000) Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. Manuscript submitted.
14. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320. doi:10.1016/j.virol.2008.02.007. PubMed: 18367229.
15. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196: 1304-1312. doi:10.1086/522428. PubMed: 17922394. (Pubitemid 351412002)
16. Plotkin SA (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409. doi:10.1086/589862. PubMed: 18558875.
17. Mann AM, Rusert P, Berlinger L, Kuster H, Günthard HF et al. (2009) HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23: 1659-1667. doi:10.1097/QAD.0b013e32832e9408. PubMed: 19581791.
18. Mascola JR (1999) Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): antibody dilution method. In: NL MichaelJH Kim. HIV Protocols. Totowa: Humana Press, Inc. pp. 309-315.
19. Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PLOS ONE 4: e4505. doi:10.1371/journal.pone.0004505. PubMed: 19229336.
20. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79: 10103-10107. doi:10.1128/JVI.79.16.10103- 10107.2005. PubMed: 16051803. (Pubitemid 41098551)
21. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519. doi:10.1073/pnas.0504658102. PubMed: 16339909. (Pubitemid 43011257)
22. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149. doi:10.1073/pnas.0630530100. PubMed: 12644702. (Pubitemid 36418171)
23. Wei X, Decker JM, Wang S, Hui H, Kappes JC et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312. doi:10.1038/ nature01470. PubMed: 12646921. (Pubitemid 36378357)
24. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R et al. (2000) Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 62: 14-24. doi:10.1002/1096- 9071(200009)62:1. PubMed: 10935983.
25. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 84: 1631-1636. doi:10.1128/JVI.01482-09. PubMed: 19923174.
26. Simek MD, Rida W, Priddy FH, Pung P, Carrow E et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348. doi:10.1128/JVI.00110-09. PubMed: 19439467.
27. Stamatatos L, Morris L, Burton DR, Mascola JR (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870. PubMed: 19525964.
28. Binley JM, Wrin T, Korber B, Zwick MB, Wang M et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252. doi:10.1128/JVI.78.23.13232-13252.2004. PubMed: 15542675. (Pubitemid 39507829)
29. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289. doi:10.1126/science.1178746. PubMed: 19729618.
30. Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M et al. (2008) Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol 82: 6869-6879. doi:10.1128/JVI.00033- 08. PubMed: 18480433. (Pubitemid 351977708)
31. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLOS ONE 5: e8805. doi:10.1371/journal.pone.0008805. PubMed: 20098712.
32. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861. doi:10.1126/science.1187659. PubMed: 20616233.
33. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470. doi:10.1038/nature10373. PubMed: 21849977.
34. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602. doi:10.1126/science.1207532. PubMed: 21835983.
35. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637. doi:10.1126/science.1207227. PubMed: 21764753.
36. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL et al. (2007) Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81: 1350-1359. doi:10.1128/JVI.01839-06. PubMed: 17079307. (Pubitemid 46167856)
37. Lynch RM, Rong R, Boliar S, Sethi A, Li B et al. (2011) The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 85: 905-915. doi:10.1128/JVI. 02006-10. PubMed: 20980495.
38. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K et al. (2008) The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82: 1860-1869. doi:10.1128/JVI.02187-07. PubMed: 18057243. (Pubitemid 351206934)
39. Moore PL, Gray ES, Morris L (2009) Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS 4: 358-363. doi: 10.1097/COH.0b013e32832ea7e8. PubMed: 20048698.
40. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598. PubMed: 19763271.
41. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J et al. (2007) Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81: 5658-5668. doi:10.1128/JVI.00257-07. PubMed: 17360739. (Pubitemid 46847005)
42. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5: e1000594. PubMed: 19763269.
43. Tang H, Robinson JE, Gnanakaran S, Li M, Rosenberg ES et al. (2011) epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. J Virol 85: 9286-9299. doi:10.1128/JVI.02286-10. PubMed: 21734041.
44. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E et al. (2008) Profiling the Specificity of Neutralizing Antibodies in a Large Panel of HIV-1 Plasmas from Subtype B and C Chronic Infections. J Virol.
45. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81: 6548-6562. doi:10.1128/JVI.02749-06. PubMed: 17409160. (Pubitemid 46878059)
46. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD et al. (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937. doi:10.1128/JVI.00758-09. PubMed: 19553335.
47. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-1034. doi:10.1038/nm1624. PubMed: 17721546. (Pubitemid 47517505)
48. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S et al. (2009) Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83: 1045-1059. doi:10.1128/JVI.01992-08. PubMed: 19004942.
49. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769. doi:10.1128/JVI.02036-08. PubMed: 18987148.
50. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K et al. (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85: 11502-11519. doi: 10.1128/JVI.05363-11. PubMed: 21849452.
51. Wei X, Decker JM, Liu H, Zhang Z, Arani RB et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905. doi:10.1128/AAC.46.6.1896-1905.2002. PubMed: 12019106. (Pubitemid 34535213)
52. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B et al. (2006) Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 348: 1107-1115. doi:10.1016/j.bbrc. 2006.07.163. PubMed: 16904645. (Pubitemid 44251203)
53. Brown BK, Karasavvas N, Beck Z, Matyas GR, Birx DL et al. (2007) Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 81: 2087-2091. doi:10.1128/JVI.02011-06. PubMed: 17151131. (Pubitemid 46214483)
54. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML et al. (2008) Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375: 529-538. doi:10.1016/j.virol.2008.02.022. PubMed: 18433824.
55. Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M et al. (2010) Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 202: 595-605. doi:10.1086/654816. PubMed: 20608874.
56. Buttke TM, Folks TM (1992) Complete replacement of membrane cholesterol with 4,4′,14-trimethyl sterols in a human T cell line defective in lanosterol demethylation. J Biol Chem 267: 8819-8826. PubMed: 1577721.
57. Folks T, Benn S, Rabson A, Theodore T, Hoggan MD et al. (1985) Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A 82: 4539-4543. doi: 10.1073/pnas.82.13.4539. PubMed: 2989831. (Pubitemid 15233156)
58. Perfetto SP, Malone JD, Hawkes C, McCrary G, August B et al. (1998) CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression. Cytometry 33: 133-137. doi:10.1002/(SICI)1097-0320(19981001)33:2. PubMed: 9773873. (Pubitemid 28447137)
59. Lazarovits AI, Moscicki RA, Kurnick JT, Camerini D, Bhan AK et al. (1984) Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 133: 1857-1862. PubMed: 6088627. (Pubitemid 14035276)
60. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367. doi:10.1128/JVI.74.18.8358-8367.2000. PubMed: 10954535. (Pubitemid 30666686)
61. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864. PubMed: 9525605. (Pubitemid 28175522)
62. Spenlehauer C, Gordon CA, Trkola A, Moore JP (2001) A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 280: 292-300. doi:10.1006/viro.2000.0780. PubMed: 11162843. (Pubitemid 34165359)
63. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP (1999) A cell line based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 73: 8966-8974. PubMed: 10516002. (Pubitemid 29487049)
64. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T et al. (2001) Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol 75: 3903-3915. doi:10.1128/JVI.75.8.3903-3915.2001. PubMed: 11264379. (Pubitemid 32246399)
65. Bihl FK, Loggi E, Chisholm JV 3rd, Hewitt HS, Henry LM et al. (2005) Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". J Transl Med 3: 20. doi:10.1186/1479-5876-3-20. PubMed: 15888204.
66. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204: 3027-3036. doi: 10.1084/jem.20070695. PubMed: 18025129. (Pubitemid 350179568)
67. Darden JM, Polonis VR, deSouza MS, Chantakulkij S, Brown AE et al. (2000) A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry 40: 141-150. doi:10.1002/(SICI)1097-0320(20000601) 40:2. PubMed: 10805934. (Pubitemid 30322377)
68. Polonis VR, De Souza MS, Chanbancherd P, Chantakulkij S, Jugsudee A et al. (2001) HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. AIDS Res Hum Retroviruses 17: 69-79. doi:10.1089/088922201750056807. PubMed: 11177385. (Pubitemid 32096427)
69. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J et al. (1999) Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 37: 2557-2563. PubMed: 10405401. (Pubitemid 29337278)
70. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA et al. (1994) Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 169: 48-54. doi:10.1093/infdis/169.1.48. PubMed: 8277197.
71. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS et al. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408: 1-13. doi:10.1016/j.virol.2010.08.028. PubMed: 20863545.
72. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J et al. (2012) Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86: 2715-2728. doi:10.1128/JVI.06157-11. PubMed: 22190722.
73. Chenine AL (2013) Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01-AE backbone. PLoS ONE. Manuscript accepted.
74. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR et al. (2005) Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J Virol 79: 10108-10125. doi:10.1128/JVI.79.16.10108-10125.2005. PubMed: 16051804. (Pubitemid 41098552)
75. Kim JH, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola JR, Frankel SS, DeSouza MS, Polonis V, McLinden RJ, Sambor A, Brown AE, Phonrat B, Rungruengthanakit K, Duliege A-M, Robb ML, McNeil J, Birx DL and the TAVEG (2003) Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody (NAb) to subtype E HIV-1. AIDS Res Hum Retroviruses 19: 807-816. doi:10.1089/088922203769232601. PubMed: 14585211. (Pubitemid 37215136)
76. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS et al. (2007) A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 46: 48-55. doi:10.1097/QAI.0b013e3181576795. PubMed: 17909315. (Pubitemid 47507433)
77. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: 301-309. doi:10.1038/ni1566. PubMed: 18264102. (Pubitemid 351267327)
78. Conley AJ, Kessler JA 2nd, Boots LJ, Tung JS, Arnold BA et al. (1994) Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A 91: 3348-3352. doi:10.1073/pnas.91.8.3348. PubMed: 7512731. (Pubitemid 24130234)
79. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP (1997) Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 71: 2779-2785 (Pubitemid 27119916)
80. Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS et al. (1997) Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 71: 7198-7206. PubMed: 9311792. (Pubitemid 27391653)
81. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905. doi:10.1128/JVI.75.22.10892-10905.2001. PubMed: 11602729. (Pubitemid 33034579)
82. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ et al. (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69: 6609-6617. PubMed: 7474069.
83. Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC et al. (2009) Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 23: 2069-2077. doi:10.1097/QAD.0b013e32832faea5. PubMed: 19710597.
84. Peachman KK, Wieczorek L, Matyas GR, Polonis VR, Alving CR et al. (2010) The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization. Viral Immunol 23: 627-632. doi:10.1089/vim.2010.0061. PubMed: 21142448.
85. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194: 1650-1660. doi:10.1086/509259. PubMed: 17109336. (Pubitemid 44901995)
86. Wang S, Kennedy JS, West K, Montefiori DC, Coley S et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26: 1098-1110. doi:10.1016/j.vaccine.2007.12.024. PubMed: 18243434.
87. Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J et al. (2003) Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 188: 219-227. doi:10.1086/376506. PubMed: 12854076. (Pubitemid 36898153)
88. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S et al. (2005) HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339: 226-238. doi:10.1016/j.virol.2005.06. 003. PubMed: 16005039. (Pubitemid 41169790)
89. Rusert P, Mann A, Huber M, von Wyl V, Gunthard HF et al. (2009) Divergent effects of cell environment on HIV entry inhibitor activity. AIDS 23: 1319-1327. doi:10.1097/QAD.0b013e32832d92c2. PubMed: 19579289.
90. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22: 339-348. doi:10.1097/QAD. 0b013e3282f3ca57. PubMed: 18195560.
91. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y et al. (2011) Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 3: 81ra36. PubMed: 21543722.
92. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P et al. (2012) Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 482: 89-93. PubMed: 22217938.
93. Hoxie JA (2010) Toward an antibody-based HIV-1 vaccine. Annu Rev Med 61: 135-152. doi:10.1146/annurev.med.60.042507.164323. PubMed: 19824826.
94. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R et al. (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: 20877-20882. doi:10.1073/pnas.0911796106. PubMed: 19933330.
95. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K et al. (2011) The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLOS Pathog 7: e1001301.
96. Ugolini S, Mondor I, Sattentau QJ (1999) HIV-1 attachment: another look. Trends Microbiol 7: 144-149. doi:10.1016/S0966-842X(99)01474-2. PubMed: 10217828.
97. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC (2009) Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol 83: 7397-7410. doi:10.1128/JVI.00656-09. PubMed: 19458010.
98. Etemad B, Fellows A, Kwambana B, Kamat A, Feng Y et al. (2009) Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol 83: 9694-9708. doi:10.1128/JVI.00925-09. PubMed: 19625411.
99. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK et al. (2010) Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 207: 763-776. doi:10.1084/jem.20091281. PubMed: 20368576.
100. Ott DE (2002) Potential roles of cellular proteins in HIV-1. Rev Med Virol 12: 359-374. doi:10.1002/rmv.367. PubMed: 12410528. (Pubitemid 35334422)
101. Rizzuto CD, Sodroski JG (1997) Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 71: 4847-4851. PubMed: 9151884. (Pubitemid 27204183)
102. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444. doi:10.1016/j.cell.2009.02.046. PubMed: 19410541.
103. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337. (Pubitemid 44901996)